ByTrending Posts
Inductive Bio and Amgen Collaborate With ARPA-H to…
United States Inductive Bio, a New York–based artificial intelligence company focused on drug discovery, has been awarded up…
Amgen Takes Steps With U.S. Government to Reduce…
Thousand Oaks, California Amgen announced that it is working with the U.S. government on new measures aimed at…
Could CagriSema Become the First Once-Weekly GLP-1 and…
United States / Denmark Novo Nordisk has submitted a New Drug Application to the U.S. Food and Drug…
U.S. FDA Awards National Priority Review Vouchers to…
United States — The U.S. Food and Drug Administration (FDA) has awarded Commissioner’s National Priority Review Vouchers to…
Pfizer Provides 2026 Financial Guidance and Updates 2025…
New York, NY – Pfizer Inc. (NYSE: PFE) today announced its financial guidance for the full year 2026…
Pfizer Celebrates Innovation with 2025 AI Festival
Global – Pfizer hosted its second annual AI Festival Week, bringing together colleagues worldwide to explore the transformative…
Eli Lilly Announces $6 Billion Pharmaceutical Manufacturing Campus…
Huntsville, AL – Eli Lilly and Company today announced plans to construct a $6 billion pharmaceutical manufacturing campus…
Novartis Canada Receives Positive Funding Recommendations for Scemblix®…
Montreal, QC – Novartis Canada today announced that the Institut national d’excellence en santé et en services sociaux…
Novartis Announces Agreement with U.S. Government to Support…
Basel, Switzerland – Novartis, a global leader in innovative medicines, today announced it has reached an agreement with…
Trending Posts
Latest Stories
Will Novartis’ January 2026 Earnings Validate the Strength of Its Focused Portfolio and Late-Stage Pipeline?
January 30, 2026 | Full-Year 2025 Earnings Preview | Innovative Medicines Outlook Novartis is scheduled…
Will Roche’s 2025 Earnings Reset the Narrative for 2026 Growth and Pipeline Confidence?
January 29, 2026 | Full-Year Earnings | Big Pharma Outlook Roche is set to publish…
Why Is Roche Returning to China for Its Next Antibody-Drug Conjugate Bet?
January 2026 – Strategic Partnerships | China Biopharma | Oncology & ADCs Roche has extended…
Roche Signals Dual Growth Strategy: Price Reform Alignment in the U.S. and Aggressive Expansion Across Oncology and Obesity
January 2026 | Pharma & Policy | Bloomberg Interview Insight Roche is positioning itself for…
Gallery
